NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF
摘要:
Disclosed herein are compounds related to nicotinate and nicotinamide riboside and methods of making and using said compounds. Also disclosed herein are methods of making nicotinic acid mononucleoside (NAMN).
NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF
摘要:
Disclosed herein are compounds related to nicotinate and nicotinamide riboside and methods of making and using said compounds. Also disclosed herein are methods of making nicotinic acid mononucleoside (NAMN).
[EN] INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE TYROSINE PHOSPHATASE DE FAIBLE POIDS MOLÉCULAIRE ET UTILISATIONS
申请人:JOLLA INST OF ALLERGY & IMMUNOLOGY
公开号:WO2016061280A1
公开(公告)日:2016-04-21
Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).
3-Cyan-pyridine, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
申请人:ARZNEIMITTELWERK DRESDEN GmbH
公开号:EP0200024A2
公开(公告)日:1986-11-05
Die Erfindung betrifft neue, in 2-Stellung mit Oxaalkylamino-, Aminoalkylamino- oder Oxaalkyloxy-Gruppen substituierte 3-Cyan-pyridine, die in 5-Stellung Pyridyl- oder Phenylreste enthalten. Die Verbindungen weisen kardiotonische, antiarrhythmische, vasodilatatorische, bronchodilatatorische sowie antiallergische Wirkungen auf.
ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF
申请人:NOVAZOI THERANOSTICS
公开号:US20170273995A1
公开(公告)日:2017-09-28
A method for treating cancer is disclosed. The method comprises administering to a subject in need thereof, an effective amount of a pharmaceutical composition comprising monoethanolamine, its prodrug or hybrid molecule or a pharmaceutically acceptable salt thereof, and a pharmaceutically effective carrier. Also disclosed is a composition comprising monoethanolamine or a pharmaceutically acceptable salt thereof and a pharmaceutically effective carrier, wherein the pharmaceutical composition is formulated for oral, intravenous, intraperitoneal, subcutaneous, dermal, or intranasal administration.